Get the Stockscreener App
24.65
0.74%
0.18
After Hours:
24.74
0.09
+0.37%
Pacira Biosciences Inc stock is traded at $24.65, with a volume of 450.10K.
It is up +0.74% in the last 24 hours and up +5.75% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$24.47
Open:
$24.47
24h Volume:
450.10K
Relative Volume:
0.51
Market Cap:
$1.16B
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
17.00
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
+4.05%
1M Performance:
+5.75%
6M Performance:
+45.43%
1Y Performance:
-7.92%
1-Day Range:
$24.33
$25.08
1-Week Range:
$23.62
$25.35
52-Week Range:
$11.16
$31.67
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
813-553-6680
Address
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
24.65 | 1.16B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
(PCRX) Investment Analysis and Advice - news.stocktradersdaily.com
Pacira (PCRX) Announces New $300M Share Repurchase Plan | PCRX Stock News - GuruFocus
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com
Pacira Biosciences IncAuthorizes $300 Million Share Repurchase Program - marketscreener.com
Pacira Biosciences Approves $300M Share Buyback - MarketWatch
Pacira BioSciences initiates $300 million buyback plan - Investing.com
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders | PCRX Stock News - GuruFocus
Pacira BioSciences Announces $300M Share Buyback and '5x30' Growth Plan: Double-Digit Revenue Growth Targeted - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Connect - markets.businessinsider.com
Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth? - Yahoo Finance
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out - markets.businessinsider.com
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listin - GuruFocus
Raymond James Financial Inc. Acquires Shares of 10,099 Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Pacira BioSciences (PCRX) Grants Inducement Awards to New Employ - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pacira's Latest Move: 66,500 Shares in Stock Awards Signal Aggressive Talent Push - Stock Titan
Sei Investments Co. Sells 7,231 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Taking the lead: Pacira BioSciences Inc (PCRX) - Sete News
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb - Yahoo Finance
Vanguard Group Inc. Decreases Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira Biosciences' SWOT analysis: stock outlook amid litigation settlement - Investing.com Australia
Pacira Biosciences' SWOT analysis: stock outlook amid litigation settlement By Investing.com - Investing.com South Africa
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More - Yahoo Finance
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act - Seeking Alpha
Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains? - Yahoo Finance
Pacira Biosciences’ SWOT analysis: stock outlook amid litigation settlement By Investing.com - Investing.com UK
Corebridge Financial Inc. Trims Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $27.22 Average Target Price from Analysts - The AM Reporter
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up After Analyst Upgrade - Defense World
Pacira Reaches IP Deal Allowing Generic Painkiller In 2030 - Law360
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
PCRX Stock Soars on Exparel Patent Settlement With Generic Players - Zacks Investment Research
Pacira Biosciences Stock Rises On Patent Litigation Settlement: Retail Sentiment Soars - MSN
Forecasting The Future: 8 Analyst Projections For Pacira BioSciences - Benzinga
Pacira Biosciences Resolves Patent Disputes, Shares Jump Over 21% - Finimize
RBC Raises Price Target on Pacira Biosciences to $26 From $22, Keeps Sector Perform Rating - MarketScreener
Truist Raises Price Target on Pacira Biosciences to $28 From $25, Keeps Hold Rating - MarketScreener
Pacira Biosciences Settles Patent Litigations Over Local Analgesic; Shares Rise Pre-bell - MarketScreener
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by American Century Companies Inc. - Defense World
Pacira BioSciences (PCRX) Shares Spike 15% After Patent Settleme - GuruFocus
Pacira surges on patent settlement with Fresenius - MSN
Pacira Pharmaceuticals Settles Patent Litigation with Fresenius - TipRanks
Pacira stock surges on patent settlement (PCRX:NASDAQ) - Seeking Alpha
Pacira Biosciences Announces Settlement Of U.S. Patent Litigation For Exparel - MarketScreener
Pacira BioSciences stock surges on patent litigation settlement By Investing.com - Investing.com Canada
Pacira BioSciences stock surges on patent litigation settlement - Investing.com Australia
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):